ECE2017 Eposter Presentations: Thyroid Thyroid (non-cancer) (260 abstracts)
1Endocrinology Department, Centro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova de Gaia/Porto, Portugal; 2Clinical Pathology Department, Centro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova de Gaia/Porto, Poland.
Introduction: Graves disease (GD) hyperthyroidism is caused by autoantibodies against TSH receptor (TRAb). Three varieties of TRAb are now recognized: stimulating (TSI), blocking and neutral antibodies. Current TRAb immunoassays detect and quantify serum immunoglobulins that interact with the TSH receptor but without discriminating their function. An automated immunoassay for the detection and quantification of TSI is available.
Objective: Our study objective was to determine the performance of TSI assay in patients with thyroid autoimmune disease, nodular disease, and healthy individuals.
Methods: 59 subjects were enrolled in the study: 37 samples of consecutive individuals referred to the endocrinology consultation with thyroid pathology and 22 healthy subjects. The Immulite® 2000 TSI (Siemens) was used to measure TSI.
Results: Of the 37 patients, 30 (81,1%) were female and 7 (18,91%) were male, with a mean age of 58 (±14) years. 18 patients were diagnosed with autoimmune thyroid diseases (10 with untreated GD and 8 with Hashimoto thyroiditis (HT)) and 19 with nodular thyroid disease (12 with non-toxic goiter and 7 with toxic adenoma). Healthy subjects and those with nodular thyroid disease had a negative TSI assay but one patient with HT had a positive TSI assay (specificity 98%). Of the ten patients with diagnosis of Graves disease 10 had positive TSI assay (sensitivity of 100%) with a median value of 3.6 IU/L (maximum of 90.1, minimum of 1.2). There was a positive correlation between the value of TSI assay and the amount of the free fractions of thyroid hormones.
Conclusion: This easy to perform assay method of TSI revealed high sensitivity and specificity in the diagnosis of Graves disease.